MedTrace Logo

Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old

NCT02806531 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2016-06-20

No results posted yet for this study

Summary

This phase IV clinical study evaluates the safety of enterovirus 71 vaccine in children aged 6-35 months old by the method of both passive and active surveillance.

Conditions

  • Enterovirus 71 Vaccine

Interventions

BIOLOGICAL

two doses enterovirus 71 vaccine

Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.

Sponsors & Collaborators

  • Beijing Chaoyang District Centre for Disease Control and Prevention

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
35 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806531 on ClinicalTrials.gov